Insight Molecular Diagnostics (IMDX) Common Equity (2020 - 2025)
Historic Common Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$9.2 million.
- Insight Molecular Diagnostics' Common Equity fell 19469.67% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.2 million, marking a year-over-year decrease of 19469.67%. This contributed to the annual value of -$12.3 million for FY2024, which is 15996.68% down from last year.
- Per Insight Molecular Diagnostics' latest filing, its Common Equity stood at -$9.2 million for Q3 2025, which was down 19469.67% from $1.1 million recorded in Q2 2025.
- Insight Molecular Diagnostics' Common Equity's 5-year high stood at $106.6 million during Q1 2021, with a 5-year trough of -$12.3 million in Q4 2024.
- Over the past 5 years, Insight Molecular Diagnostics' median Common Equity value was $34.3 million (recorded in 2022), while the average stood at $39.9 million.
- In the last 5 years, Insight Molecular Diagnostics' Common Equity skyrocketed by 19113.45% in 2021 and then crashed by 19469.67% in 2025.
- Over the past 5 years, Insight Molecular Diagnostics' Common Equity (Quarter) stood at $65.2 million in 2021, then crashed by 47.42% to $34.3 million in 2022, then tumbled by 40.31% to $20.5 million in 2023, then crashed by 159.97% to -$12.3 million in 2024, then grew by 25.08% to -$9.2 million in 2025.
- Its Common Equity stands at -$9.2 million for Q3 2025, versus $1.1 million for Q2 2025 and $10.2 million for Q1 2025.